TC
REGN icon

Truvestments Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Truvestments Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.7K Sell
99
-6
-6% -$4.08K 0.01% 488
2026
Q1 		$81.1K Hold
105
– – 0.01% 424
2025
Q4 		$81K Buy
105
+53
+102% +$36K 0.01% 372
2025
Q3 		$29.3K Buy
52
+10
+24% +$5.65K 0.01% 522
2025
Q2 		$22.1K Buy
42
+26
+163% +$14.5K ﹤0.01% 519
2025
Q1 		$10.1K Sell
16
-26
-62% -$17.9K ﹤0.01% 654
2024
Q4 		$29.9K Buy
42
+5
+14% +$4.2K 0.01% 446
2024
Q3 		$38.9K Buy
+37
New +$41.2K 0.01% 392
2024
Q2 		– Sell
-8
Closed -$7.7K – 577
2024
Q1 		$7.7K Hold
8
– – ﹤0.01% 515
2023
Q4 		$7.03K Hold
8
– – ﹤0.01% 552
2023
Q3 		$6.58K Hold
8
– – ﹤0.01% 483
2023
Q2 		$5.75K Hold
8
– – ﹤0.01% 513
2023
Q1 		$6.57K Buy
8
+5
+167% +$3.77K ﹤0.01% 476
2022
Q4 		$2.16K Hold
3
– – ﹤0.01% 713
2022
Q3 		$2K Hold
3
– – ﹤0.01% 567
2022
Q2 		$2K Buy
+3
New +$1.95K ﹤0.01% 573

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Truvestments Capital's REGN Position: Q2 2026 in Review

Truvestments Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 5.7% in Q2 2026, selling an estimated $4.08K and leaving 99 shares worth $61.7K. The position accounts for 0.01% of the portfolio, ranked #488.

Truvestments Capital first reported a position in REGN in Q2 2022 and has held it in 16 quarters since. The position peaked at $81.1K in Q1 2026. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Truvestments Capital held 99 shares of Regeneron Pharmaceuticals worth $61.7K as of Q2 2026.
  • Truvestments Capital sold 6 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.08K.
  • Regeneron Pharmaceuticals made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #488 holding.
  • Truvestments Capital first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • Truvestments Capital's Regeneron Pharmaceuticals position peaked at $81.1K in Q1 2026.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.